


Jing Lu, Ph.D.^{1*}, Yimin Qian, Ph.D.^{1*}, Kanak Raina, PhD^{1*}, Martha Altieri, MS^{1*}, Hanqing Dong, PhD^{1*}, Jing Wang, PhD^{1*}, Xin Chen, PhD^{1*}, Andrew Crew, PhD^{1*}, Kevin Coleman, PhD^{1*}, Craig Crews, PhD^{2*} and **James Winkler, PhD¹**
¹Arvinas, LLC, New Haven, CT. ²Department of Molecular, Cellular, and Developmental Biology, Department of Chemistry, Department of Pharmacology, Yale University, New Haven, CT


Abstract:

- BRD4, a member of the bromodomain and extraterminal domain (BET) family, has emerged as an attractive oncology target
- BET bromodomain inhibitors have shown promising results in certain preclinical settings, including diffuse large B-cell lymphoma (DLBCL)
- We have designed a Proteolysis Targeting Chimera (PROTAC) ARV-771, a heterobifunctional small molecule containing a BRD4 binding moiety and a ligand for the E3 ubiquitin ligase VHL
- ARV-771 treatment leads to rapid and efficient degradation of BRD4 and provides more pronounced and longer-lasting effect in suppressing c-MYC levels than small molecule BRD4 inhibitors
- BRD4 PROTACs are more effective in suppressing proliferation and inducing apoptosis in DLBCL compared to BRD4 inhibitors
- BRD4 PROTACs induce profound alterations in signaling molecules crucial for apoptosis in DLBCL

ARV-771 is a potent BRD4 degrader in DLBCL cell lines




ARV-771 leads to more significant suppression of DLBCL cell proliferation than the BET inhibitor OTX015





ARV-766, a non-VHL binding diastereomer of ARV-771, has no anti-proliferative activity


ARV-771 induces significant changes of signaling molecules crucial for apoptosis




PROTAC: PROteolysis TArgeting Chimera




BRD4 degradation by ARV-771 is blocked by pretreatment with an excess of the VHL ligand ARV-056 and with a proteasome inhibitor



PROTAC-mediated BRD4 degradation is rapid, and is achieved within 8h of treatment



ARV-771 leads to more pronounced apoptosis in DLBCL cells than the BET inhibitor OTX015*



* as measured by the Caspase 3/7 Glo Assay (Promega)

Summary

- We have developed a BRD4 PROTAC (ARV-771) that degrades BRD4 potently and rapidly
- ARV-771 has significantly greater anti-proliferative and apoptotic activity in DLBCL cells than the BET inhibitor OTX015
- The anti-proliferative effect of ARV-771 is accompanied by profound changes in apoptotic/survival signaling pathways in DLBCL cells
- PROTAC-mediated degradation of BRD4 provides a more effective strategy in targeting BRD4 than traditional small molecule inhibitors
- Our study demonstrates that the PROTAC platform, by actively recruiting E3 ligase to target pathological proteins for degradation, is a promising strategy for the development of novel therapeutics